SEC Form 4 · accession 0001114220-18-000052
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jodie Pope Morrison
Officer — Interim CEO · Director
Period of report
May 10, 2018
Accepted (ET)
May 14, 2018 · 9:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 10, 2018 | A | 100,000 | $0.00 | A | 110,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 100,000 shares are restricted common stock, which will vest in full on October 31, 2018, conditioned upon Ms. Morrison's continued employment as Interim CEO and subject to other terms and conditions.
- F2Includes 110,000 shares of restricted stock.